Literature DB >> 16260188

Optimal number of repeated measures and group sizes in clinical trials with linearly divergent treatment effects.

Bjorn Winkens1, Hubert J A Schouten, Gerard J P van Breukelen, Martijn P F Berger.   

Abstract

The effect of number of repeated measures on the variance of the generalized least squares (GLS) treatment effect estimator is considered assuming a linearly divergent treatment effect, equidistant time-points and either a fixed number of subjects or a fixed study budget. The optimal combination of group sizes and number of repeated measures is calculated by minimizing this variance subject to a linear cost function. For a fixed number of subjects, the variance of the GLS treatment effect estimator can be decreased by adding intermediate measures per subject. This decrease is relatively large if a) the covariance structure is compound symmetric or b) the structure approaches compound symmetry and the correlation between two repeated measures does not exceed 0.80, or c) the correlation between two repeated measures does not exceed 0.60 if the time-lag goes to zero. In case the sample sizes and number of repeated measures are limited by budget constraints and the covariance structure includes a first-order auto-regression part, two repeated measures per subject yield highly efficient treatment effect estimators. Otherwise, it is more efficient to have more than two repeated measures. If the covariance structure is unknown, the optimal design based on a first-order auto-regressive structure with measurement error is preferable in terms of robustness against misspecification of the covariance structure. The numerical results are illustrated by three examples.

Mesh:

Year:  2005        PMID: 16260188     DOI: 10.1016/j.cct.2005.09.005

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  6 in total

1.  Adding Subjects or Adding Measurements in Repeated Measurement Studies Under Financial Constraints.

Authors:  Song Zhang; Chul Ahn
Journal:  Stat Biopharm Res       Date:  2011-02-01       Impact factor: 1.452

2.  Optimal design of studies of influenza transmission in households. I: case-ascertained studies.

Authors:  B Klick; G M Leung; B J Cowling
Journal:  Epidemiol Infect       Date:  2011-03-22       Impact factor: 2.451

3.  Optimal combination of number of participants and number of repeated measurements in longitudinal studies with time-varying exposure.

Authors:  Jose Barrera-Gómez; Donna Spiegelman; Xavier Basagaña
Journal:  Stat Med       Date:  2013-06-05       Impact factor: 2.373

4.  Designing clinical trials to test disease-modifying agents: application to the treatment trials of Alzheimer's disease.

Authors:  Chengjie Xiong; Gerald van Belle; J Philip Miller; John C Morris
Journal:  Clin Trials       Date:  2011-02       Impact factor: 2.486

5.  Two to five repeated measurements per patient reduced the required sample size considerably in a randomized clinical trial for patients with inflammatory rheumatic diseases.

Authors:  Geir Smedslund; Heidi Andersen Zangi; Petter Mowinckel; Kåre Birger Hagen
Journal:  BMC Res Notes       Date:  2013-02-01

6.  The Neurocognitive Study for the Aging: Longitudinal Analysis on the Contribution of Sex, Age, Education and APOE ɛ4 on Cognitive Performance.

Authors:  Andreas Chadjikyprianou; Marilena Hadjivassiliou; Savvas Papacostas; Fofi Constantinidou
Journal:  Front Genet       Date:  2021-07-13       Impact factor: 4.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.